.svg){kind=small}
May-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
In May 2026, Vireo’s mix concentrated into two categories: Concentrates at 81.39% share and Topical at 18.61% share, with month-over-month gains of 22.22% and 130.26% respectively that contrast with a brand-level year-over-year sales decline of 73.60%. Year-over-year category growth diverged sharply, with Concentrates up 268.64% and Topical up 299.51%, while the average price climbed 55.97% to $41.46 and Concentrates commanded a higher ticket at 46.88. The pattern implies that category-level expansion in Concentrates and Topical is offsetting contraction elsewhere in the portfolio, concentrating revenue into higher-price segments despite overall brand contraction.
Within New York Concentrates, Vireo’s rank at 33 and an 81.39% sales share anchored in Concentrates indicate a positioning shift toward potency-forward formats, while a 130.26% month-over-month surge in Topical and a 299.51% year-over-year increase signal opportunistic growth in an ancillary wellness lane. The juxtaposition of a 22.22% month-over-month rise in Concentrates alongside a 55.97% year-over-year price increase suggests a trade-up effect rather than purely volume-led recovery, and the 18.61% Topical share provides diversification headroom without diluting the Concentrates-led identity. The pattern implies Vireo is concentrating its competitive posture in Concentrates while using Topical as a volatility buffer, with pricing power supporting rank stability at 33.
Competitive Landscape
Vireo sits at rank 33 in NY Concentrates in May 2026, a 5-position improvement from rank 38 year over year, while its peak at rank 31 in June 2025 places the current position 2 spots below that high-water mark. Competitive pressure is intensifying as Jetpacks advanced from rank 4 to rank 2 and RYTHM climbed from rank 5 to rank 3, compared with Vireo’s 0-position change from February 2026 to May 2026 and a 5-position gain versus May 2025; this contrast indicates rivals are converting larger share gains even as Vireo edges up the table. The pattern implies Vireo’s modest rank recovery is at risk of stalling unless it accelerates gains to close the 2-rank gap to its June 2025 peak amid faster-moving competitors.
Notable Products
CBD/THC 1:19 Red Balm (5mg CBD, 95mg THC, 1.5oz) delivered the standout move in May 2026 with a 452.2% month-over-month surge to $3,893 and entered the top tier at rank 2, while Sativa RSO Syringe (1g) fell 12.3% and still held rank 1. Hybrid RSO Syringe (1g) climbed 69.1% to rank 2 and Indica RSO Syringe (1g) rose 55.5% to rank 3, establishing that three of the top three ranks are Concentrates SKUs. The Topical portfolio was mixed, with the CBD/THC 1:1 Green Balm (50mg CBD, 50mg THC, 1.5oz) dropping 24.6% at rank 4 even as the high-THC Red Balm accelerated 452.2% and joined the top two. The pattern implies Vireo is concentrating demand around RSO-based Concentrates while selectively scaling high-THC Topicals, indicating a tilt toward potency-led offerings and away from balanced Topicals.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
